← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Allogene remains a clinical-stage cell-therapy company with narrower losses and no FY2025 revenue.
The read at a glance✓ Audited against SEC data
- Business — Off-the-shelf allogeneic T cell therapiesNote
- Revenue — Revenue -100.0% to $0Watch
- Profitability — Net loss narrowed 25.9%OK
- Cash quality — Operating cash flow improved 25.5%OK
- Accounting — Altman-Z -13.1001 distress; M/EQ N/AWatch
- Insiders — 0 purchases / 14 salesWatch
Business
Allogene develops genetically engineered allogeneic T cell product candidates for cancer and autoimmune diseases. The economic bet is off-the-shelf cell therapy: donor-derived T cells that can be manufactured into inventory rather than made separately for each patient.
Where the revenue comes from
Fiscal 2024, as Allogene Therapeutics, Inc. reports it. History and quarterly detail are in the app.
Leadership changes
From Allogene Therapeutics, Inc.'s own filings, the day they're filed.
- Timothy Moore · departureeff. 2025-01-23
- Annie Yoshiyama · principal accounting officer · appointmenteff. 2024-06-05
- Geoffrey Parker · President · appointmenteff. 2023-10-16
Latest filings
- 8-K · Company announcement2026-09-02
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-05-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Allogene Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.